New Study Published on BRIXADI® for Treating Opioid Dependence in Pregnant Women

New Study on BRIXADI® for Pregnant Women with Opioid Use Disorder

In a significant advancement for maternal healthcare, a new randomized clinical trial funded by the National Institutes of Health (NIH) has been published, offering promising insights into the treatment of opioid use disorder (OUD) in pregnant women. This study, appearing in JAMA Internal Medicine, specifically evaluates the efficacy of the weekly formulation of BRIXADI® (buprenorphine) compared to traditional sublingual buprenorphine for treating OUD during pregnancy and the subsequent twelve months postpartum.

Context of the Study

Opioid use disorder in pregnant women represents a critical public health issue in the United States, with estimates suggesting that approximately 2-3% of pregnancies involve this disorder. This translates to about 1 in every 40 pregnancies being affected, highlighting the urgency for effective treatment solutions that consider the unique needs of this population.

Principal investigator Dr. John Winhusen, a professor at the University of Cincinnati College of Medicine, stated, "Pregnant and postpartum individuals with opioid use disorder face enormous challenges. The trial results support the use of weekly extended-release buprenorphine for treating these individuals."

Study Design and Findings

Conducted across 13 sites in the U.S. from July 2020 to November 2024, this open-label trial included 140 participants, randomly assigned to receive either weekly extended-release buprenorphine or sublingual buprenorphine. The primary goal was to measure illicit opioid abstinence during pregnancy, assessed through urine drug screenings.

Noteworthy results indicated that participants receiving the weekly formulation experienced a significantly higher rate of abstinence from illicit opioids: 82.5% compared to 72.6% in the sublingual group, with this difference marked as statistically significant (p=0.009). Additionally, the rates of serious adverse events were notably lower in the extended-release group throughout both the pregnancy (8.7% vs. 26.8%) and postpartum periods (6.0% vs. 18.6%), suggesting a better safety profile for this treatment option.

Implications for Clinical Practice

Mike Derkacz, President and CEO of Braeburn, emphasized the significance of these findings: "The MOMs Study is the first randomized clinical trial to evaluate an extended-release buprenorphine in pregnant and postpartum individuals with OUD. Demonstrating statistical superiority in illicit opioid abstinence during pregnancy, along with fewer serious adverse events, provides clinicians and patients with important evidence to inform treatment decisions during such a crucial period."

Moreover, while the study demonstrated compelling benefits of weekly BRIXADI®, there were noted limitations including data constraints on secondary outcomes and a lack of diversity in the participant population. These aspects call for further research to ensure comprehensive understanding and applicability across broader demographics.

About BRIXADI®

BRIXADI® is specifically designed to support individuals struggling with opioid use disorder and is typically prescribed alongside counseling and behavioral therapy to enhance treatment outcomes. However, practitioners must remain vigilant about the risks associated with its use, including the potential for addiction, respiratory depression, and other severe side effects.

In light of these findings, BRIXADI® could represent a transformative option for treatment protocols among pregnant women struggling with opioid dependence, ultimately contributing to better maternal and neonatal health outcomes.

For those seeking detailed insights, the complete study titled 'Extended-release versus Sublingual Buprenorphine for Opioid Use Disorder in Pregnancy through 12-months Postpartum' is accessible online at JAMA Internal Medicine.

Further Considerations

As the delivery of effective treatment strategies continues to evolve, the insights gained from this study can help shape guidelines and improve care frameworks for pregnant individuals grappling with opioid use disorder. The ongoing dialogue surrounding treatment methodologies must prioritize both safety and efficacy to ensure optimal outcomes for mothers and their children.